Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Active:	Yes
Cancer Type:	Bile Duct Cancer Gallbladder Cancer	NCT ID:	NCT06282575
Trial Phases:	Phase III	Protocol IDs:	JZP598-302 (primary) NCI-2024-03767 2023-508219-21-00
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Jazz Pharmaceuticals
NCI Full Details:	http://clinicaltrials.gov/show/NCT06282575

Summary

The purpose of this study is to evaluate the efficacy and safety of Zanidatamab plus
CisGem (Cisplatin and Gemcitabine) with or without the addition of a programmed death
protein 1/ligand-1 (PD-1/L1) inhibitor (physician's choice of either Durvalumab or
Pembrolizumab, where approved under local regulations) as first line of treatment for
participants with human epidermal growth factor receptor 2 (HER2)-positive biliary tract
cancer.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.